BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 18230961)

  • 1. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
    Fisman EZ; Motro M; Tenenbaum A
    Adv Cardiol; 2008; 45():154-170. PubMed ID: 18230961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2009 Jul; 8():38. PubMed ID: 19619327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
    Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M
    Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of antidiabetic therapies on cardiovascular disease.
    Panunti B; Kunhiraman B; Fonseca V
    Curr Atheroscler Rep; 2005 Feb; 7(1):50-7. PubMed ID: 15683603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes and oral antihyperglycemic drugs.
    Mizuno CS; Chittiboyina AG; Kurtz TW; Pershadsingh HA; Avery MA
    Curr Med Chem; 2008; 15(1):61-74. PubMed ID: 18220763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into antidiabetic drugs: Possible applications in cancer treatment.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Zarghami N
    Chem Biol Drug Des; 2017 Dec; 90(6):1056-1066. PubMed ID: 28456998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral antidiabetic agents: recent aspects].
    Keller U; Berger W
    Schweiz Med Wochenschr; 1983 Apr; 113(17):645-50. PubMed ID: 6191388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antidiabetic drugs: an overview.
    Melander A
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
    Jawa AA; Fonseca VA
    Cardiol Clin; 2005 May; 23(2):119-38. PubMed ID: 15694742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
    Purnell JQ; Weyer C
    Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
    Bolen S; Feldman L; Vassy J; Wilson L; Yeh HC; Marinopoulos S; Wiley C; Selvin E; Wilson R; Bass EB; Brancati FL
    Ann Intern Med; 2007 Sep; 147(6):386-99. PubMed ID: 17638715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 2 diabetes mellitus: pharmacologic intervention.
    McCormick M; Quinn L
    J Cardiovasc Nurs; 2002 Jan; 16(2):55-67. PubMed ID: 11800068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.